During the course on patient centricity in clinical studies you will learn about the role of patients and how patient centricity translates into the clinical development of medicines, diagnostics and medical devices. You will also learn more about engaging and recruiting patients for clinical studies.
Clinical development is an important domain of health care. It is one step in the process of bringing new medicines or treatments to the market. It is based on non-clinical research (in microorganisms/animals) and refers to the clinical studies conducted in humans that consist of several phases. Clinical studies investigate and confirm the safety and efficacy of new drugs, diagnostics and medical devices before they are marketed.
The culture of clinical development is evolving from one directed by researchers to one driven by patient needs and perspectives. Patients are no longer seen as mere subjects who generate data but as informed collaborators whose participation is vital for the overall success of clinical trials. Patient-oriented clinical development is increasingly becoming the model that the industry follows. Patient centricity means designing a clinical trial around the patient. Clinical trials often struggle with both patient enrolment and retention. Creating a patient-centric solution involves getting feedback from patients themselves and making decisions based on their needs and perspectives. Identifying and addressing unmet patient needs has become a key goal in clinical research. Patient-centric approaches to clinical trials are harnessed to achieve this goal.
But what does it mean to be patient centric, practically speaking? What tactics are leading pharma companies employing to make patient centricity a reality in their trials? What does patient centricity mean for your role? And what does it mean from a patient perspective? This course is intended to provide an answer to these questions through lectures, testimonies and a panel discussion. You will learn how the biopharmaceutical industry collaborates with patient organizations in the clinical development of new medicines, diagnostics and medical devices. From contributing to the design of a clinical trial and improving the readability of the informed consent to providing valuable advice in making patient recruitment and retention more efficient. You will also learn how patient organizations help to communicate the existence of a clinical study within the group of interested patients.
Download the programme here.
The aim is to organise the course physically. We have experience in organising trainings for small groups in COVID19 times. The necessary measures will be taken to organise the course safely and with attention to social distancing and hygiene. Only when measures taken by the government prevent us from organising a physical course, a digital alternative will be organised.
When? From 18-19 November 2020.
Where? Flanders.bio, Jean-Baptiste de Ghellincklaan 13/0102, 9051 Ghent, Belgium.
Registration fee? The registration fee for the one and a half day course is €150 (excl. VAT) for non-members and €125 (excl. VAT) for flanders.bio members, VIVES employees and students.
Registrations are open until the 19th of October 2020.
To allow the course to be safely organised the number of registrations will be limited to 10.
Find more information and register here.
If you cross the border to live, work, study or do business in Belgium, Germany or the Netherlands, you will have to deal with the rules and obligations of that country. It may be unclear to you what this entails; for more information regarding the consequences of emigration or cross-border work, please follow the link: Border information point provides answers to these and other questions.